Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162119PMC
http://dx.doi.org/10.31486/toj.18.0011DOI Listing

Publication Analysis

Top Keywords

utilization lcp-tacrolimus
4
lcp-tacrolimus envarsus
4
envarsus simultaneous
4
simultaneous pancreas
4
pancreas kidney
4
kidney transplant
4
transplant recipients
4
utilization
1
envarsus
1
simultaneous
1

Similar Publications

Article Synopsis
  • LCPT (Envarsus XR®) is an extended-release tacrolimus used in kidney transplants, but there's a lack of clear guidelines on its dosing and use in new patients or those switching from other forms.
  • A group of 12 experts used the Delphi method to create and refine consensus statements on LCPT use, achieving significant agreement on 18 out of 23 generated statements after two rounds of feedback.
  • Key findings included that LCPT is recommended as a first-line option for new patients, especially African Americans and rapid metabolizers, and that conversion to LCPT is effective for mitigating neurological side effects from immediate-release tacrolimus.
View Article and Find Full Text PDF

The use of LCP-Tacrolimus (Envarsus XR) in simultaneous pancreas and kidney (SPK) transplant recipients.

Am J Surg

April 2020

Albert Einstein College of Medicine, Bronx, NY, USA; Montefiore-Einstein Center for Transplantation, Montefiore Medical Center, Bronx, NY, USA. Electronic address:

Background: Extended release LCP-tacrolimus (LCPT) allows once-daily dosing in transplant recipients. The improved bioavailability may be beneficial for simultaneous pancreas-kidney recipients (SPK).

Methods: This is a study of 39 SPK recipients on standard immediate-release tacrolimus (IR-TAC, n = 21) or LCPT (n = 18).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!